NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
AstraZeneca launches and prices a €750,000,000 7 year bond issue
AstraZeneca PLC, rated A2 (stable outlook) by Moody's and AA- (negative outlook) by Standard & Poor's, announces today the successful pricing of euro medium term notes in an aggregate principal amount of €750,000,000 maturing on 24 November 2021 with a coupon of 0.875% (the "Notes").
The proceeds of the issue will be used to fund the repayment of outstanding euro medium term notes in an aggregate principal amount of €750,000,000 maturing in January 2015.
The Notes are being issued under the U.S.$5,000,000,000 Euro Medium Term Note Programme of AstraZeneca PLC.
The Notes will be issued to institutional investors outside the US in accordance with Regulation S of the U.S. Securities Act of 1933, as amended. The Notes will be admitted to listing on the UK Listing Authority's Official List and to trading on the London Stock Exchange's regulated market.
Notes to editors
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com.
